Futura Medical Share Chat (FUM)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Futura Medical	LSE:FUM	London	Ordinary Share	GB0033278473	ORD 0.2P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.15p	+1.54%	9.90p	9.80p	10.00p	9.90p	9.65p	9.75p	540,245	09:47:35

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.4	-4.8	-3.2	-	20.43

Futura Medical Share Discussion Threads

Showing 16626 to 16646 of 16650 messages

Chat Pages: 666 665 664 663 662 661 660 659 658 657 656 655 Older

Date	Subject	Author	Discuss
17/1/2019 09:57	What is really eye opening,is that even if Fum ended up with the same $75 million that Eli Lilly paid to Icos upfront after only a phase 2 trial result,would equate to 30p a share to Fum.Smell the coffee time !	j777j	Read Full Thread Reply
16/1/2019 12:45	"The Directors plan to take MED2002 through Phase 3 development and then seek to partner or sell the asset. However, in parallel, the Directors propose to continue discussions with potential licencees for MED2002."4 months further down the line and I would definitely not bet against a deal coming at any time.Med2002 is highly disruptive and it is just a matter of time before a Pharma jumps in rather than risk losing out to another Pharma.	j777j	Read Full Thread Reply
16/1/2019 12:25	really thats why it move from 16p to over 50p after P2 results hehe. troll	ih_116147	Read Full Thread Reply
16/1/2019 10:09	You rampers are going to have to find another product because med 2002 is having zero effect on this SP!	slaccs	Read Full Thread Reply
16/1/2019 08:54	Market cap 20 million /Cash 10.5 million / Drug potential 2 BILLION = Lifetime Opportunity Futura Medical featured in Growth Company Investor recommendations 08 January 2019 CEO James Barder describes Futura as a â€œmedtechâ€;� rather than biotech business. Its proprietary technology is DermaSys which delivers drugs rapidly through the skin and into the blood system. The lead product is MED2005 which is a topical gel for erectile dysfunction. The main advantage over Viagra is that it takes effect within five minutes, compared with over an hour for the famous blue pills. Which ensures key ingredients of spontaneity and mood can be retained while the treatment works. Research suggests a 20% market share could be possible, equating to sales of $560m in major western markets. In time an OTC version could more than double this.	ih_116147	Read Full Thread Reply
15/1/2019 16:58	what did you pay?	mikethebike4	Read Full Thread Reply
15/1/2019 15:04	added another 20k shares news could come in anytime now	bioking	Read Full Thread Reply
14/1/2019 11:00	If you guys want the stock to make bigger moves then please put your shares on high GTC sell order like 50p this helps to prevent your shares from being shorted and more important your shares will not be available on the market so if all shareholders doing that then it would help this stock to make bigger jumps in share price on good news. thank you hxxp://www.contracts-for-difference.com/Borrowing-lending-shares.html Q:What can you do to prevent your shares holdings from being shorted? A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account. There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are ‘on order’ they cannot be lent out by your broker and in turn you are reducing the amount of ‘free shares’ out there that can be used for shorting purposes. And don’t forget to move your limit order up when the price starts to recover, then, that way your shares can’t be shorted – not much but helps :D. Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on. In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own.	bioking	Read Full Thread Reply
14/1/2019 10:42	would like nothing better than to be proven wrong !	mikethebike4	Read Full Thread Reply
14/1/2019 09:29	6p ? lol keep dreaming you will never see that number again 50p is more likely than your 6p ..	bioking	Read Full Thread Reply
14/1/2019 09:16	slow post-ramp slide back down to 6p ?	mikethebike4	Read Full Thread Reply
14/1/2019 00:51	FUM has the most EFFECTIVE AND SAFEST Potency Drug even BILLION Dollar Drugs like Viagra and Cialis looks like garbage compared to FUMs Med2002 and this company is still valued at ridicouls 20 million which is more than a pure gift . Furutra could get 20% of a US$5bn market Futura Medical PLC’s (LON:FUM) erectile dysfunction treatment, MED 2002 has the potential to be a US$1bn drug, new research has suggested. Sales of that magnitude would put the gel into the blockbuster category. Market research firm Ipsos, interviewed 400 men to asses the gel's potential as an OTC or without prescription product. Respondents indicated the rapid onset of action, an average of less than five minutes, was the key feature and could command a price premium compared with existing treatments such as Viagra and Cialis, which have a substantially slower onset. That made it 'highly differentiated' from the rivals. Ipsos, which a strong record in forecasting drug sales, predicts peak OTC or without prescription annual sales for MED2002 in excess of US$650mln, of which 70% would be in addition to previous estimates of a US$600mln prescription market. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions would be more than US$1bn under patent.	bioking	Read Full Thread Reply
12/1/2019 11:04	"You rampers are better off finding a little corner and joining the MED2002 trial!" That seems to be exactly what they are doing.	joestalin	Read Full Thread Reply
11/1/2019 14:16	bought another 20k shares thanks	ih_572003	Read Full Thread Reply
11/1/2019 11:24	nice consolidation ongoing after 60% jump ,next big leg up coming .any dip here is a great buying opp.	ih_572003	Read Full Thread Reply
11/1/2019 10:26	desperate ? lol im deep in green with fum	bioking	Read Full Thread Reply
11/1/2019 10:17	bioking You sound desperate.	montyhedge	Read Full Thread Reply
11/1/2019 10:15	You rampers are better off finding a little corner and joining the MED2002 trial!	slaccs	Read Full Thread Reply
11/1/2019 09:37	Market cap 20 million / 11 million cash / Drug potential 2 BILLION = £2++ stock trading at 10p a lifetime opp CEO James Barder describes Futura as a “medtech”; rather than biotech business. Its proprietary technology is DermaSys which delivers drugs rapidly through the skin and into the blood system. The lead product is MED2005 which is a topical gel for erectile dysfunction. The main advantage over Viagra is that it takes effect within five minutes, compared with over an hour for the famous blue pills. Which ensures key ingredients of spontaneity and mood can be retained while the treatment works. Research suggests a 20% market share could be possible, equating to sales of $560m in major western markets. In time an OTC version could more than double this.	bioking	Read Full Thread Reply
11/1/2019 09:25	You rampers are better off finding a little corner and joining the MED2002 trial!	slaccs	Read Full Thread Reply
11/1/2019 09:13	Furutra could get 20% of a US$5bn market Futura Medical PLC’s (LON:FUM) erectile dysfunction treatment, MED 2002 has the potential to be a US$1bn drug, new research has suggested. Sales of that magnitude would put the gel into the blockbuster category. Market research firm Ipsos, interviewed 400 men to asses the gel’s potential as an OTC or without prescription product. Respondents indicated the rapid onset of action, an average of less than five minutes, was the key feature and could command a price premium compared with existing treatments such as Viagra and Cialis, which have a substantially slower onset. That made it ‘highly differentiated’; from the rivals. Ipsos, which a strong record in forecasting drug sales, predicts peak OTC or without prescription annual sales for MED2002 in excess of US$650mln, of which 70% would be in addition to previous estimates of a US$600mln prescription market. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions would be more than US$1bn under patent.	bioking	Read Full Thread Reply

Chat Pages: 666 665 664 663 662 661 660 659 658 657 656 655 Older